Lorenzo-Almorós A, Pello A, Aceña Á, Martínez-Milla J, González-Lorenzo Ó, Tarín N, Cristóbal C, Blanco-Colio L M, Martín-Ventura J L, Huelmos A, Gutiérrez-Landaluce C, López-Castillo M, Kallmeyer A, Cánovas E, Alonso J, Bescós L López, Egido J, Lorenzo Ó, Tuñón J
Department of Internal Medicine, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.
Laboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.
J Clin Med. 2020 Apr 13;9(4):1105. doi: 10.3390/jcm9041105.
Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population.
We followed 964 patients with coronary artery disease (CAD), assessing plasma levels of galectin-3, monocyte chemoattractant protein-1 (MCP-1), and N-terminal fragment of brain natriuretic peptide (NT-proBNP) at baseline. The secondary outcomes were acute ischemia and heart failure or death. The primary outcome was the combination of the secondary outcomes.
Two hundred thirty-two patients had T2DM. Patients with T2DM showed higher MCP-1 (144 (113-195) vs. 133 (105-173) pg/mL, = 0.006) and galectin-3 (8.3 (6.5-10.5) vs. 7.8 (5.9-9.8) ng/mL, = 0.049) levels as compared to patients without diabetes. Median follow-up was 5.39 years (2.81-6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients (Hazard ratio (HR) 1.57 (1.07-2.30); = 0.022), along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in nondiabetic patients (HR 1.21 (1.04-1.42); = 0.017 and HR 1.23 (1.05-1.44); = 0.012, respectively), along with male sex and age. Galectin-3 was also the only biomarker associated with the development of acute ischemic events and heart failure or death in T2DM patients, while, in nondiabetics, MCP-1 and NT-proBNP, respectively, were related to these events.
In CAD patients, galectin-3 plasma levels are associated with cardiovascular events in patients with T2DM, and MCP-1 and NT-proBNP in those without T2DM.
2型糖尿病（T2DM）与早期严重动脉粥样硬化相关。然而，很少有生物标志物能够预测该人群的心血管事件。
我们对964例冠心病（CAD）患者进行随访，在基线时评估其血浆半乳糖凝集素-3、单核细胞趋化蛋白-1（MCP-1）和脑钠肽N端片段（NT-proBNP）水平。次要结局为急性缺血、心力衰竭或死亡。主要结局为次要结局的综合情况。
232例患者患有T2DM。与非糖尿病患者相比，T2DM患者的MCP-1水平更高（144（113 - 195）对133（105 - 173）pg/mL，P = 0.006），半乳糖凝集素-3水平也更高（8.3（6.5 - 10.5）对7.8（5.9 - 9.8）ng/mL，P = 0.049）。中位随访时间为5.39年（2.81 - 6.92）。在T2DM患者中，半乳糖凝集素-3水平与主要结局风险增加相关（风险比（HR）1.57（1.07 - 2.30）；P = 0.0
